ArticleHepatology (Baltimore, Md.)2022

Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.

Leidy D Caraballo Galva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.